In this randomized controlled trial, inebilizumab, an anti-CD19 monoclonal antibody, reduced the risk of flares and increased ...

Results from Phase II studies demonstrated that rilzabrutinib showed clinically meaningful outcomes in patients with warm ...

New diagnostic criteria are enhancing accuracy in identifying IgG4-related periaortitis, periarteritis, and retroperitoneal ...

The Food and Drug Administration (FDA) has approved Uplizna ® (inebilizumab-cdon) for the treatment of immunoglobulin G4-related disease (IgG4-RD) in adult patients.

Inebilizumab-cdon was previously approved by the FDA for neuromyelitis optica spectrum disorder (NMOSD) in adults who are ...

The FDA on Thursday gave the green light to Uplizna in IgG4-related disease, making it the first and only approved treatment ...

Uplizna is the first approved treatment for immunoglobulin G4-related disease (IgG4-RD), a chronic inflammatory condition ...

Leerink analysts noted, however, that Uplizna’s slow onset of therapeutic efficacy compares unfavorably to would-be ...

Inebilizumab-cdon (Uplizna; Amgen) was approved as the first and only treatment for immunoglobulin G4–related disease ...

The FDA approved Amgen ’s anti-CD19 therapy Uplizna Thursday for use in patients with IgG4-related disease. Uplizna is the ...

Advances Amgen’s Leadership in CD19 Directed, B-Cell Depletion Therapies for Serious Autoimmune Diseases Including NMOSD, IgG4-RD and gMG THOUSAND OAKS, CA, USA I April 3, 2025 I Amgen (NASDAQ:AMGN) ...